2018
Brief Report
Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, Springer S, Chandler R, Kahana S, Crane HM. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 283-287. PMID: 30036277, PMCID: PMC6681811, DOI: 10.1097/qai.0000000000001803.Peer-Reviewed Original ResearchConceptsPHQ-9 scoresDepressive symptomsSubstance useATS useLower oddsMean decreaseAmphetamine-type substancesAIDS Research NetworkCocaine/crack useDepressive symptom scoresMental health disordersJoint longitudinal-survival modelCocaine/crackPoor outcomeSymptom scoresPHQ-9Health disordersIllicit opiatesSymptomsPLWHLongitudinal assessmentSite cohortSubstance use frequencyCrack useAbstinence
2009
Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-983. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.Peer-Reviewed Original ResearchConceptsInjection drug usersCES-D scoresMajor depressive disorderAntiretroviral therapyCD4 countDepressive symptomsDrug usersDrug useHIV-1 RNA levelsProspective clinical trialsSubstance abuse treatment servicesSelf-administered therapyActive drug useNon-Caucasian raceSix-month followSix-month dataAntidepressant medicationAntiretroviral treatmentPoor adherenceSymptomatic responseMale genderClinical trialsDepressive disorderDepression ScaleDrug treatment